Figure 6.

Sensitivity analyses using (A) the Dirichlet SLoS model; (B) the Dirichlet linear model; (C) the Dirichlet product model. IVO, ivosidenib; PBO, placebo; SLoS, Scale Loss Score. Benefit criteria: progression-free survival, overall survival, objective response rate, and quality of life (Quality of Life Questionnaire Physical Functioning, Pain, and Appetite Loss subscales). Risk criteria: electrocardiogram QT prolonged, gastrointestinal (diarrhea, vomiting, nausea), fatigue, adverse events leading to treatment discontinuation, and adverse events leading to dose reduction.